Updates and Controversies in the Rapidly Evolving Field of Lung Cancer Screening, Early Detection, and Chemoprevention

Cancers

Hasmeena Kathuria²  Yaron Gesthalter²  Avrum Spira¹  Jerome S. Brody² 

[1]Division of Computational Biomedicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA

[2] E-Mails:

[3]The Pulmonary Center, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA

[4] E-Mails:

关键词: lung cancer;    screening;    early detection;    chemoprevention;   

DOI  :  10.3390/cancers6021157

来源: mdpi

【 摘 要 】

Lung cancer remains the leading cause of cancer-related death in the United States. Cigarette smoking is a well-recognized risk factor for lung cancer, and a sustained elevation of lung cancer risk persists even after smoking cessation. Despite identifiable risk factors, there has been minimal improvement in mortality for patients with lung cancer primarily stemming from diagnosis at a late stage when there are few effective therapeutic options. Early detection of lung cancer and effective screening of high-risk individuals may help improve lung cancer mortality. While low dose computerized tomography (LDCT) screening of high risk smokers has been shown to reduce lung cancer mortality, the high rates of false positives and potential for over-diagnosis have raised questions on how to best implement lung cancer screening. The rapidly evolving field of lung cancer screening and early-detection biomarkers may ultimately improve the ability to diagnose lung cancer in its early stages, identify smokers at highest-risk for this disease, and target chemoprevention strategies. This review aims to provide an overview of the opportunities and challenges related to lung cancer screening, the field of biomarker development for early lung cancer detection, and the future of lung cancer chemoprevention.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.